26th June 2025
25th June 2025
āshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)
4th June 2025
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
28th May 2025
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
28th May 2025
Aktis Oncology Initiates Phase 1b Clinical Trial Of Its Nectin-4- Targeting Radiopharmaceutical Product Candidate, Aky-1189, Across Multiple Tumor Types
13th October 2023
GBR’s USA Life Sciences 2023 Report featuring Chris Bardon
10th October 2023
AstronauTx Closes $61M Series A to Create New Alzheimer’s Treatments
28th September 2023
Deka Biosciences Closes USD $20 Million Series B2 Financing
21st September 2023
The Endpoints 11: Biotech Startups With the Most Exciting Science
19th September 2023